Existing investors Celgene and Astellas returned to back the virus-based cancer therapy developer's $79.5m series B round to take its total funding to more than $140m.
US-based cancer treatment developer Oncorus closed a $79.5m series B round yesterday that included pharmaceutical firms Celgene and Astellas, the latter through subsidiary Astellas Venture Management.
The oversubscribed round was co-led by Cowen Healthcare Investments and Perceptive Advisors and included UBS Oncology Impact Fund and Shinhan Investment-Private Equity, representatives of financial services firms UBS and Shinhan.
MPM Capital – which also backs UBS Oncology Impact Fund – also took part, as did Deerfield Management, Arkin Bioventures, Surveyor Capital, Sphera Funds,…
